Dr. Neelapu on Long-Term Follow-Up of ZUMA-5 With Axicabtagene Ciloleucel in R/R Non-Hodgkin Lymphoma

Video

Sattva S. Neelapu, MD, discusses the long-term follow-up analysis of the phase 2 ZUMA-5 trial with axicabtagene ciloleucel in patients with relapsed/refractory indolent non-Hodgkin lymphoma. 

Sattva S. Neelapu, MD, a professor and deputy department chair in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the long-term follow-up analysis of the phase 2 ZUMA-5 trial (NCT03105336) with axicabtagene ciloleucel (Yescarta) in patients with relapsed/refractory indolent non-Hodgkin lymphoma. 

At the 2021 ASH Annual Meeting and Exposition, updated findings from the ZUMA-5 trial were presented with at least 2 years of follow-up, Neelapu says. Altogether, 149 patients were treated on the study. Among the efficacy-evaluable population (n = 110), the complete response rate was 79% in patients with follicular lymphoma and 63% in patients with marginal zone lymphoma (MZL), Neelapu explains.

After a median follow-up of 30.9 months in the follicular lymphoma cohort, 57% of patients remain in ongoing response, and the estimated median PFS was about 39.6 months, Neelapu continues. In the MZL cohort, the median follow-up was 23.8 months and 50% of the patients remain in remission, Neelapu concludes. 

Related Videos
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Vikram M. Narayan, MD
C. Ola Landgren, MD, PhD
Timothy Yap, MBBS, PhD, FRCP
Muhamed Baljevic, MD, FACP
Kathleen A. Dorritie, MD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Muhamed Baljevic, MD